← feed

Is NCT03053089 results overdue?

Yes — results are overdue. Primary completion was 2018-02-01; the FDAAA-801 reporting deadline (2019-02-01) passed 2697 days ago and no results are posted on ClinicalTrials.gov.

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

NCT IDNCT03053089 ↗
SponsorArmaGen, Inc (INDUSTRY)
PhasePHASE1, PHASE2
StatusCOMPLETED
Primary completion2018-02-01 (ACTUAL)
Reporting deadline2019-02-01 (completion + 365d)
Days overdue2697
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 79c8729620e4a278… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03053089. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →